News
BMYMP
400.00
-57.46%
-540.22
Weekly Report: what happened at BMYMP last week (0309-0313)?
Weekly Report · 03/16 09:39
Weekly Report: what happened at BMYMP last week (0302-0306)?
Weekly Report · 03/09 09:41
DHS: Dividend ETF With Balanced Portfolio, But Average Results
Seeking Alpha · 03/04 11:00
Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution
Seeking Alpha · 03/03 18:50
Top 10 Healthcare Stocks of February
Seeking Alpha · 03/02 20:31
Weekly Report: what happened at BMYMP last week (0223-0227)?
Weekly Report · 03/02 09:40
Weekly Report: what happened at BMYMP last week (0216-0220)?
Weekly Report · 02/23 09:39
This Is A Stock Picker's Market
Seeking Alpha · 02/19 22:20
Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength
Seeking Alpha · 02/19 16:28
Weekly Report: what happened at BMYMP last week (0209-0213)?
Weekly Report · 02/16 09:39
Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff
Seeking Alpha · 02/11 15:00
Weekly Report: what happened at BMYMP last week (0202-0206)?
Weekly Report · 02/09 09:41
Bristol-Myers Squibb outlines $46B–$47.5B 2026 revenue target as growth portfolio nears 60% of sales, driven by new product launches and pipeline catalysts
Seeking Alpha · 02/05 23:05
Weekly Report: what happened at BMYMP last week (0126-0130)?
Weekly Report · 02/02 09:40
Weekly Report: what happened at BMYMP last week (0119-0123)?
Weekly Report · 01/26 09:40
Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion
Seeking Alpha · 01/23 20:52
Weekly Report: what happened at BMYMP last week (0112-0116)?
Weekly Report · 01/19 09:44
XLV Vs. BME: Total Return Or Income, Which Healthcare Strategy Wins?
Seeking Alpha · 01/14 17:39
Weekly Report: what happened at BMYMP last week (0105-0109)?
Weekly Report · 01/12 09:42
Weekly Report: what happened at BMYMP last week (1229-0102)?
Weekly Report · 01/05 09:40
More
Webull provides a variety of real-time BMYMP stock news. You can receive the latest news about Bristol Myers through multiple platforms. This information may help you make smarter investment decisions.
About BMYMP
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).